<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33802046</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2801</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22062801</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica (NMO) is an immune-mediated demyelinative disorder of the central nervous system affecting mainly the optical nerves and the spinal cord. The recurrent course of the disease, with exacerbations and incomplete remissions, causes accumulating disability, which has a profound impact upon patients' quality of life. The discovery of antibodies against aquaporin 4 (AQP4) and their leading role in NMO etiology and the formulation of diagnostic criteria have improved appropriate recognition of the disease. In recent years, there has been rapid progress in understanding the background of NMO, leading to an increasing range of treatment options. On the basis of a review of the relevant literature, the authors present currently available therapeutic strategies for NMO as well as ongoing research in this field, with reference to key points of immune-mediated processes involved in the background of the disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Waliszewska-Prosół</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-9074-2803</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Wroclaw Medical University, 50-556 Wroclaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chojdak-Łukasiewicz</LastName>
            <ForeName>Justyna</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-0777-4565</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Wroclaw Medical University, 50-556 Wroclaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Budrewicz</LastName>
            <ForeName>Sławomir</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Wroclaw Medical University, 50-556 Wroclaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pokryszko-Dragan</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Wroclaw Medical University, 50-556 Wroclaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009900" MajorTopicYN="N">Optic Nerve</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aquaporin 4</Keyword>
        <Keyword MajorTopicYN="N">autoimmune humoral response</Keyword>
        <Keyword MajorTopicYN="N">demyelinating diseases</Keyword>
        <Keyword MajorTopicYN="N">neuromyelitis optica spectrum disorder</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>1</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33802046</ArticleId>
        <ArticleId IdType="pmc">PMC7998461</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22062801</ArticleId>
        <ArticleId IdType="pii">ijms22062801</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Devic E.  Congrès Français de Médecine (Premiere Session; Lyon, 1894; Procès-Verbaux, Mémoires et Discussions) Asselin et Houzeau; Louis Savy; Lyon, France: Paris, France: 1895. Myélite aiguë dorso-lombaire avec névrite optique—Autopsie; pp. 434–439.</Citation>
        </Reference>
        <Reference>
          <Citation>Lennon A.V., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364:2106–2112. doi: 10.1016/S0140-6736(04)17551-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(04)17551-X</ArticleId>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damiza-Detmer A., Milewska-Jędrzejczak M., Pawełczyk M., Damiza I., Głąbiński A. Neuromyelitis optica spectrum disorder (NMOSD)—Diagnosis, epidemiology, clinical course, treatment. Aktualności Neurol. 2019;19:19–26. doi: 10.15557/AN.2019.0004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15557/AN.2019.0004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collongues N., Ayme-Dietrich E., Monassier L., De Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs. 2019;79:125–142. doi: 10.1007/s40265-018-1039-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-018-1039-7</ArticleId>
            <ArticleId IdType="pubmed">30623348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Lennon A.V., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815. doi: 10.1016/S1474-4422(07)70216-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(07)70216-8</ArticleId>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Banwell B., Bennett J.L., Cabre P., Carroll W., Chitnis T., De Seze J., Fujihara K., Greenberg B.M., Jacob A., et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rego C.A.D., Collongues N. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev. Neurol. 2018;174:458–470. doi: 10.1016/j.neurol.2018.02.084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2018.02.084</ArticleId>
            <ArticleId IdType="pubmed">29685427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujihara K., Cook L.J. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: Current topics. Curr. Opin. Neurol. 2020;33:300–308. doi: 10.1097/WCO.0000000000000828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000828</ArticleId>
            <ArticleId IdType="pubmed">32374571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brod S.A. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult. Scler. Relat. Disord. 2020;46:102538. doi: 10.1016/j.msard.2020.102538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102538</ArticleId>
            <ArticleId IdType="pmc">PMC7539063</ArticleId>
            <ArticleId IdType="pubmed">33059216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandit L., Asgari N., Apiwattanakul M., the GJCF International Clinical Consortium &amp; Biorepository for Neuromyelitis Optica  Demographic and clinical features of neuromyelitis optica: A review. Mult. Scler. 2015;21:845–853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4463026</ArticleId>
            <ArticleId IdType="pubmed">25921037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Zhong L., Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult. Scler. Relat. Disord. 2019;27:412–418. doi: 10.1016/j.msard.2018.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.12.002</ArticleId>
            <ArticleId IdType="pubmed">30530071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandler R.N. Neuromyelitis optica—Devic’s syndrome, update. Autoimmun. Rev. 2006;5:537–543. doi: 10.1016/j.autrev.2006.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2006.02.008</ArticleId>
            <ArticleId IdType="pubmed">17027889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshii F., Moriya Y., Ohnuki T., Ryo M., Takahashi W. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord. 2016;7:53–57. doi: 10.1016/j.msard.2016.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2016.03.004</ArticleId>
            <ArticleId IdType="pubmed">27237757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L., Asavapanumas N., Verkman A.S. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin. Ther. Targets. 2020;24:219–229. doi: 10.1080/14728222.2020.1732927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14728222.2020.1732927</ArticleId>
            <ArticleId IdType="pmc">PMC7941255</ArticleId>
            <ArticleId IdType="pubmed">32070155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selmaj K., Selmaj I. Novel emerging treatments for NMOSD. Neurol. Neurochir. Pol. 2019;53:317–326. doi: 10.5603/PJNNS.a2019.0049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/PJNNS.a2019.0049</ArticleId>
            <ArticleId IdType="pubmed">31664710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett B., Greenberg A. Traboulsee, Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled Phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD) J. Neurol. Sci. 2019;25:44.</Citation>
        </Reference>
        <Reference>
          <Citation>Papadopoulos M., Verkman A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–544. doi: 10.1016/S1474-4422(12)70133-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70133-3</ArticleId>
            <ArticleId IdType="pmc">PMC3678971</ArticleId>
            <ArticleId IdType="pubmed">22608667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., Glogowska M., Case D., Antel J.P., Owens G.P., et al.  Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009;66:617–629. doi: 10.1002/ana.21802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21802</ArticleId>
            <ArticleId IdType="pmc">PMC3180961</ArticleId>
            <ArticleId IdType="pubmed">19938104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frampton J.E. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Drugs. 2020;80:719–727. doi: 10.1007/s40265-020-01297-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01297-w</ArticleId>
            <ArticleId IdType="pmc">PMC7183484</ArticleId>
            <ArticleId IdType="pubmed">32266705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceglie G., Papetti L., Valeriani M., Merli P. Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. Int. J. Mol. Sci. 2020;21:5304.  doi: 10.3390/ijms21155304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21155304</ArticleId>
            <ArticleId IdType="pmc">PMC7432050</ArticleId>
            <ArticleId IdType="pubmed">32722601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosso M., Saxena S., Chitnis T. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: A review of emerging treatment options. Expert Rev. Neurother. 2020;20:509–516. doi: 10.1080/14737175.2020.1757434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737175.2020.1757434</ArticleId>
            <ArticleId IdType="pubmed">32306778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linhares U.C., Schiavoni P.B., Barros P.O. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J. Clin. Immunol. 2013;33:179–189. doi: 10.1007/s10875-012-9780-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-012-9780-2</ArticleId>
            <ArticleId IdType="pubmed">22948743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M. Blockade of IL-6 signaling in neuromyelitis optica. Neurochem. Int. 2019;130:104315. doi: 10.1016/j.neuint.2018.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2018.10.012</ArticleId>
            <ArticleId IdType="pubmed">30342072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takai Y., Misu T., Kaneko K., Chihara N., Narikawa K., Tsuchida S., Nishida H., Komori T., Seki M., Komatsu T., et al.  Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study. Brain. 2020;143:1431–1446. doi: 10.1093/brain/awaa102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa102</ArticleId>
            <ArticleId IdType="pubmed">32412053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L., Asavapanumas N., Verkman A.S. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol. Pharmacol. 2013;83:1268–1275. doi: 10.1124/mol.113.086470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.113.086470</ArticleId>
            <ArticleId IdType="pmc">PMC3657102</ArticleId>
            <ArticleId IdType="pubmed">23571414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu F., Schaller K.L., Owens G.P., Cotleur A.C., Kellner D., Takeshita Y., Obermeier B., Kryzer T.J., Sano Y., Kanda T., et al.  Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci. Transl. Med. 2017;9:eaai9111. doi: 10.1126/scitranslmed.aai9111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aai9111</ArticleId>
            <ArticleId IdType="pmc">PMC5585784</ArticleId>
            <ArticleId IdType="pubmed">28679661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B., Paul F. Neuromyelitis optica: Clinical features, immunopathogenesis and treatment. Clin. Exp. Immunol. 2014;176:149–164. doi: 10.1111/cei.12271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12271</ArticleId>
            <ArticleId IdType="pmc">PMC3992027</ArticleId>
            <ArticleId IdType="pubmed">24666204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruck W., Popescu B., Lucchinetti C.F., Markovic-Plese S., Gold R., Thal D.R., Metz I. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann. Neurol. 2012;72:385–394. doi: 10.1002/ana.23621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23621</ArticleId>
            <ArticleId IdType="pubmed">23034911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trebst C., Neuromyelitis Optica Study Group (NEMOS) Jarius S., Berthele A., Paul F., Schippling S., Wildemann B., Borisow N., Kleiter I., Aktas O., et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) J. Neurol. 2014;261:1–16. doi: 10.1007/s00415-013-7169-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7169-7</ArticleId>
            <ArticleId IdType="pmc">PMC3895189</ArticleId>
            <ArticleId IdType="pubmed">24272588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleiter I., Gahlen A., Borisow N., Fischer K., Wernecke K.-D., Wegner B., Hellwig K., Pache F., Ruprecht K., Havla J., et al.  Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses. Ann. Neurol. 2016;79:206–216. doi: 10.1002/ana.24554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24554</ArticleId>
            <ArticleId IdType="pubmed">26537743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimbrough D.J., Fujihara K., Jacob A., Lana-Peixoto M.A., Leite M.I., Levy M., Marignier R., Nakashima I., Palace J., De Seze J., et al.  Treatment of neuromyelitis optica: Review and recommendations. Mult. Scler. Relat. Disord. 2012;1:180–187. doi: 10.1016/j.msard.2012.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2012.06.002</ArticleId>
            <ArticleId IdType="pmc">PMC3926208</ArticleId>
            <ArticleId IdType="pubmed">24555176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiebel-Kalish H., Hellmann M.A., Mimouni M., Paul F., Bialer O., Bach M., Lotan I. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol. Neuroimmunol. Neuroinflamm. 2019;6:e572. doi: 10.1212/NXI.0000000000000572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000572</ArticleId>
            <ArticleId IdType="pmc">PMC6624092</ArticleId>
            <ArticleId IdType="pubmed">31355308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T., Nakashima I., Takahashi T., Abe M., Ishii T., Aoki M. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e640. doi: 10.1212/NXI.0000000000000640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000640</ArticleId>
            <ArticleId IdType="pmc">PMC6935841</ArticleId>
            <ArticleId IdType="pubmed">31757816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.-H., Kim W., Huh S.-Y., Lee K.Y., Jung I.J., Kim H.J. Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels. J. Clin. Neurol. 2013;9:36–42. doi: 10.3988/jcn.2013.9.1.36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2013.9.1.36</ArticleId>
            <ArticleId IdType="pmc">PMC3543908</ArticleId>
            <ArticleId IdType="pubmed">23346159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magaña S.M., Keegan B.M., Weinshenker B.G., Erickson B.J., Pittock S.J., Lennon V.A., Rodriguez M., Thomsen K.M., Weigand S.D., Mandrekar J., et al.  Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Arch. Neurol. 2011;68:870–878. doi: 10.1001/archneurol.2011.34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.34</ArticleId>
            <ArticleId IdType="pmc">PMC3134547</ArticleId>
            <ArticleId IdType="pubmed">21403003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merle H., Olindo S., Jeannin S., Valentino R., Mehdaoui H., Cabot F., Donnio A., Hage R., Richer R., Smadja D., et al.  Treatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica. Arch. Ophthalmol. 2012;130:858–862. doi: 10.1001/archophthalmol.2012.1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archophthalmol.2012.1126</ArticleId>
            <ArticleId IdType="pubmed">22776923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe S., Nakashima I., Misu T., Miyazawa I., Shiga Y., Fujihara K., Itoyama Y. Therapeutic efficacy of plasma exchange in nmo-igg-positive patients with neuromyelitis optica. Mult. Scler. 2007;13:128–132. doi: 10.1177/1352458506071174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458506071174</ArticleId>
            <ArticleId IdType="pubmed">17294622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shemin D., Briggs D., Greenan M. Complications of therapeutic plasma exchange: A prospective study of 1727 procedures. J. Clin. Apher. 2007;22:270–276. doi: 10.1002/jca.20143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jca.20143</ArticleId>
            <ArticleId IdType="pubmed">17722046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleiter I., Gahlen A., Borisow N., Fischer K., Wernecke K.D., Hellwig K. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol. Neuroimmunol. Neuroinflamm. 2018;26:e504. doi: 10.1212/NXI.0000000000000504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000504</ArticleId>
            <ArticleId IdType="pmc">PMC6192689</ArticleId>
            <ArticleId IdType="pubmed">30345331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faissner S., Nikolayczik J., Chan A., Gold R., Yoon M.-S., Haghikia A. Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther. Adv. Neurol. Disord. 2016;9:281–286. doi: 10.1177/1756285616646332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756285616646332</ArticleId>
            <ArticleId IdType="pmc">PMC4916525</ArticleId>
            <ArticleId IdType="pubmed">27366234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann F., Kraft A., Heigl F., Mauch E., Koehler J., Harms L., Kümpfel T., Köhler W., Ehrlich S., Bayas A., et al.  Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther. Adv. Neurol. Disord. 2018;11 doi: 10.1177/1756286418774973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286418774973</ArticleId>
            <ArticleId IdType="pmc">PMC5974561</ArticleId>
            <ArticleId IdType="pubmed">29872456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sellner J., Boggild M., Clanet M., Hintzen R.Q., Illes Z., Montalban X., Du Pasquier R.A., Polman C.H., Sorensen P.S., Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol. 2010;17:1019–1032. doi: 10.1111/j.1468-1331.2010.03066.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03066.x</ArticleId>
            <ArticleId IdType="pubmed">20528913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Wang Q., Ren H.-T., Qiao L., Zhang Y., Fei Y.-Y., Zhao Y., Cui L.-Y. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. J. Neurol. Sci. 2016;370:224–228. doi: 10.1016/j.jns.2016.09.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.09.035</ArticleId>
            <ArticleId IdType="pubmed">27772764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsone L., Panicker J., Mutch K., Boggild M., Appleton R., Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Mult. Scler. J. 2013;20:501–504. doi: 10.1177/1352458513495938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458513495938</ArticleId>
            <ArticleId IdType="pubmed">23986097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altunrende B., Akdal G., Bajin M.S., Yaman A., Kocaslan M., Nalbantoğlu M., Ertaşoğlu H., Akman G. Intravenous Immunoglobulin Treatment for Recurrent Optic Neuritis. Noropsikiyatr. Ars. 2019;56:3–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6427084</ArticleId>
            <ArticleId IdType="pubmed">30911229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso Y.D., Sousa N.A.C., Alves-Leon S.V., Dias R.M., Pimentel M.L.V., Gomes S. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD) Mult. Scler. Relat. 2019;27:392–396. doi: 10.1016/j.msard.2018.11.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.11.031</ArticleId>
            <ArticleId IdType="pubmed">30504040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K., van Doorn P.A. Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs. 2009;29:987–1001. doi: 10.2165/00003495-200969080-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003495-200969080-00004</ArticleId>
            <ArticleId IdType="pubmed">19496628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandler R.N., Ahmed W., Dencoff J.E. Devic’s neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219–1220. doi: 10.1212/WNL.51.4.1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.4.1219</ArticleId>
            <ArticleId IdType="pubmed">9781568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espiritu A.I., Pasco P.M.D. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2019;33:22–32. doi: 10.1016/j.msard.2019.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.05.011</ArticleId>
            <ArticleId IdType="pubmed">31136907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.-H., Kim W., Park M.S., Sohn E.H., Li X.F., Kim H.J. Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica. Arch. Neurol. 2011;68:473–479. doi: 10.1001/archneurol.2010.322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2010.322</ArticleId>
            <ArticleId IdType="pubmed">21149806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabre P., Olindo S., Marignier R., Jeannin S., Merle H., Smadja D., under the Aegis of the French National Observatory of Multiple Sclerosis  Efficacy of mitoxantrone in neuromyelitis optica spectrum: Clinical and neuroradiological study. J. Neurol. Neurosurg. Psychiatry. 2012;84:511–516. doi: 10.1136/jnnp-2012-303121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-303121</ArticleId>
            <ArticleId IdType="pubmed">23138769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaguchi H., Sakushima K., Takahashi I., Nishimura H., Yashima-Yamada M., Nakamura M., Tsuzaka K., Maruo Y., Takahashi T., Yabe I., et al.  Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder. Intern. Med. 2013;52:969–972. doi: 10.2169/internalmedicine.52.7885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.52.7885</ArticleId>
            <ArticleId IdType="pubmed">23648715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kageyama T., Komori M., Miyamoto K., Ozaki A., Suenaga T., Takahashi R., Kusunoki S., Matsumoto S., Kondo T. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J. Neurol. 2012;260:627–634. doi: 10.1007/s00415-012-6692-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-012-6692-2</ArticleId>
            <ArticleId IdType="pubmed">23076828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh S.-Y., Kim S.-H., Hyun J.-W., Joung A.-R., Park M.S., Kim B.-J., Kim H.J. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2014;71:1372–1378. doi: 10.1001/jamaneurol.2014.2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2057</ArticleId>
            <ArticleId IdType="pubmed">25199960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montcuquet A., Collongues N., Papeix C., Zephir H., Audoin B., Laplaud D., Bourre B., Brochet B., Camdessanche J.P., Labauge P., et al.  NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult. Scler. 2017;23:1377–1384. doi: 10.1177/1352458516678474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458516678474</ArticleId>
            <ArticleId IdType="pubmed">27885065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahara M., Oeda T., Okada K., Kiriyama T., Ochi K., Maruyama H., Fukaura H., Nomura K., Shimizu Y., Mori M., et al.  Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:298–306. doi: 10.1016/S1474-4422(20)30066-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30066-1</ArticleId>
            <ArticleId IdType="pubmed">32199095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao F., Chai B., Gu C., Wu R., Dong T., Yao Y., Zhang Y. Effectiveness of rituximab in neuromyelitis optica: A meta-analysis. BMC Neurol. 2019;19:36.  doi: 10.1186/s12883-019-1261-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-019-1261-2</ArticleId>
            <ArticleId IdType="pmc">PMC6402122</ArticleId>
            <ArticleId IdType="pubmed">30841862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong I.H., Park B., Kim S.-H., Hyun J.-W., Joo J., Kim H.J. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult. Scler. J. 2016;22:329–339. doi: 10.1177/1352458515587752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515587752</ArticleId>
            <ArticleId IdType="pubmed">26041804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D., Gallagher S., Monson N.L., Herbst R., Wang Y. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med. 2016;5:107.  doi: 10.3390/jcm5120107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm5120107</ArticleId>
            <ArticleId IdType="pmc">PMC5184780</ArticleId>
            <ArticleId IdType="pubmed">27886126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree B.A.C., Bennett J.L., Kim H.J., Weinshenker B.G., Pittock S.J., Wingerchuk D.M., Fujihara K., Paul F., Cutter G.R., Marignier R., et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–1363. doi: 10.1016/S0140-6736(19)31817-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31817-3</ArticleId>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frampton J.E. Inebilizumab: First Approval. Drugs. 2020;80:1259–1264. doi: 10.1007/s40265-020-01370-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01370-4</ArticleId>
            <ArticleId IdType="pmc">PMC7387876</ArticleId>
            <ArticleId IdType="pubmed">32729016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy M. Interleukin-6 receptor blockade for the treatment of NMOSD. Lancet Neurol. 2020;19:370–371. doi: 10.1016/S1474-4422(20)30081-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30081-8</ArticleId>
            <ArticleId IdType="pubmed">32333886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T., Narazaki M., Kishimoto T. Therapeutic Targeting of the Interleukin-6 Receptor. Annu. Rev. Pharmacol. Toxicol. 2012;52:199–219. doi: 10.1146/annurev-pharmtox-010611-134715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-010611-134715</ArticleId>
            <ArticleId IdType="pubmed">21910626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringelstein M., Ayzenberg I., Harmel J., Lauenstein A.-S., Lensch E., Stögbauer F., Hellwig K., Ellrichmann G., Stettner M., Chan A., et al.  Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015;72:756–763. doi: 10.1001/jamaneurol.2015.0533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.0533</ArticleId>
            <ArticleId IdType="pubmed">25985228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C., Zhang M., Qiu W., Ma H., Zhang X., Zhu Z., Yang C.-S., Jia D., Zhang T.-X., Yuan M., et al.  Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): An open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391–401. doi: 10.1016/S1474-4422(20)30070-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30070-3</ArticleId>
            <ArticleId IdType="pmc">PMC7935423</ArticleId>
            <ArticleId IdType="pubmed">32333897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M., Matsuoka T., Miyamoto K., Kusunoki S., Okamoto T., Murata M., Miyake S., Aranami T., Yamamura T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology. 2014;82:1302–1306. doi: 10.1212/WNL.0000000000000317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000317</ArticleId>
            <ArticleId IdType="pmc">PMC4001188</ArticleId>
            <ArticleId IdType="pubmed">24634453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan I., Charlson R.W., Ryerson L.Z., Levy M., Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult. Scler. Relat. Disord. 2020;39:101920. doi: 10.1016/j.msard.2019.101920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.101920</ArticleId>
            <ArticleId IdType="pubmed">31918241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traboulsee A., Greenberg B.M., Bennett J.L., Szczechowski L., Fox E., Shkrobot S., Yamamura T., Terada Y., Kawata Y., Wright P., et al.  Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402–412. doi: 10.1016/S1474-4422(20)30078-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30078-8</ArticleId>
            <ArticleId IdType="pmc">PMC7935419</ArticleId>
            <ArticleId IdType="pubmed">32333898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao X., Verkman A.S. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol. Commun. 2017;5:1–10. doi: 10.1186/s40478-017-0462-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-017-0462-4</ArticleId>
            <ArticleId IdType="pmc">PMC5532786</ArticleId>
            <ArticleId IdType="pubmed">28750658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lennon V.A., McKeon A., Mandrekar J., Weinshenker B.G., Lucchinetti C.F., O’Toole O., Wingerchuk D.M. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol. 2013;12:554–562. doi: 10.1016/S1474-4422(13)70076-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70076-0</ArticleId>
            <ArticleId IdType="pubmed">23623397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Berthele A., Fujihara K., Kim H.J., Levy M., Palace J., Nakashima I., Terzi M., Totolyan N., Viswanathan S., et al.  Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. N. Engl. J. Med. 2019;381:614–625. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giglhuber K., Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy. 2020;12:1053–1066. doi: 10.2217/imt-2020-0163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2020-0163</ArticleId>
            <ArticleId IdType="pubmed">32772617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardo S., Giovannoni G., Hawkes C., Lechner-Scott J., Waubant E., Levy M. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord. 2019;33:A1–A2. doi: 10.1016/j.msard.2019.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.07.001</ArticleId>
            <ArticleId IdType="pubmed">31324299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Q., Sun M., Sun J., Zheng T., Wang M. New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review) Exp. Ther. Med. 2020;21:1. doi: 10.3892/etm.2020.9579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2020.9579</ArticleId>
            <ArticleId IdType="pmc">PMC7791914</ArticleId>
            <ArticleId IdType="pubmed">33456515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo A.R., Segal B.M. Treatment of neuromyelitis optica spectrum disorders. Curr. Opin. Rheumatol. 2019;31:250–255. doi: 10.1097/BOR.0000000000000603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000603</ArticleId>
            <ArticleId IdType="pubmed">30920972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traub J., Husseini L., Weber M.S. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals. 2021;14:37.  doi: 10.3390/ph14010037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14010037</ArticleId>
            <ArticleId IdType="pmc">PMC7825598</ArticleId>
            <ArticleId IdType="pubmed">33419217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H., Biba A., Dalakas M.C. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics. 2016;13:20–33. doi: 10.1007/s13311-015-0402-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0402-6</ArticleId>
            <ArticleId IdType="pmc">PMC4720683</ArticleId>
            <ArticleId IdType="pubmed">26566961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L., Duan T., Yeaman M.R., Verkman A.S. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. J. Neuroinflamm. 2019;16:57. doi: 10.1186/s12974-019-1448-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-019-1448-x</ArticleId>
            <ArticleId IdType="pmc">PMC6408857</ArticleId>
            <ArticleId IdType="pubmed">30851734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L., Zhang H., Saadoun S., Phuan P.-W., Lam C., Papadopoulos M.C., Bennett J.L., Verkman A.S. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 2011;71:314–322. doi: 10.1002/ana.22657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22657</ArticleId>
            <ArticleId IdType="pmc">PMC3314396</ArticleId>
            <ArticleId IdType="pubmed">22271321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Verkman A. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J. Clin. Investig. 2013;123:2306–2316. doi: 10.1172/JCI67554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI67554</ArticleId>
            <ArticleId IdType="pmc">PMC3635742</ArticleId>
            <ArticleId IdType="pubmed">23563310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sand I.K., Fabian M.T., Telford R., Kraus T.A., Chehade M., Masilamani M., Moran T., Farrell C., Ebel S., Cook L.J., et al.  Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e441. doi: 10.1212/NXI.0000000000000441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000441</ArticleId>
            <ArticleId IdType="pmc">PMC6201737</ArticleId>
            <ArticleId IdType="pubmed">30426035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herges K., De Jong A.B., Kolkowitz I., Dunn C., Mandelbaum G., Ko R.M., Maini A., Han M.H., Killestein J., Polman C., et al.  Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult. Scler. J. 2012;18:398–408. doi: 10.1177/1352458512440060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458512440060</ArticleId>
            <ArticleId IdType="pmc">PMC3319834</ArticleId>
            <ArticleId IdType="pubmed">22343184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saadoun S., Waters P., Macdonald C., Bell B.A., Vincent A., Verkman A., Papadopoulos M.C. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann. Neurol. 2011;71:323–333. doi: 10.1002/ana.22686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22686</ArticleId>
            <ArticleId IdType="pmc">PMC3643520</ArticleId>
            <ArticleId IdType="pubmed">22374891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T.H., Kalden J.R., A Manz R., et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008;14:748–755. doi: 10.1038/nm1763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1763</ArticleId>
            <ArticleId IdType="pubmed">18542049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C., Tian D.-C., Yang C.-S., Han B., Wang J., Yang L., Shi F.-D. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2017;74:1010–1012. doi: 10.1001/jamaneurol.2017.1336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2017.1336</ArticleId>
            <ArticleId IdType="pmc">PMC5822186</ArticleId>
            <ArticleId IdType="pubmed">28692708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharrack B., Saccardi R., Alexander T., Badoglio M., Burman J., Farge D., Greco R., Jessop H., Kazmi M., Kirgizov K., et al.  Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: Updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) Bone Marrow Transplant. 2020;55:283–306. doi: 10.1038/s41409-019-0684-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41409-019-0684-0</ArticleId>
            <ArticleId IdType="pmc">PMC6995781</ArticleId>
            <ArticleId IdType="pubmed">31558790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng F., Qiu W., Li J., Hu X., Huang R., Lin D., Bao J., Jiang Y., Bian L. A Preliminary Result of Treatment of Neuromyelitis Optica With Autologous Peripheral Hematopoietic Stem Cell Transplantation. Neurologist. 2010;16:375–378. doi: 10.1097/NRL.0b013e3181b126e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NRL.0b013e3181b126e3</ArticleId>
            <ArticleId IdType="pubmed">21150387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greco R., Bondanza A., Oliveira M.C., Badoglio M., Burman J., Piehl F., Hagglund H., Krasulova E., Simões B.P., Carlson K., et al.  Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Mult. Scler. J. 2015;21:189–197. doi: 10.1177/1352458514541978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514541978</ArticleId>
            <ArticleId IdType="pubmed">25078274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matiello M., Pittock S.J., Porrata L., Weinshenker B.G. Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica. Arch. Neurol. 2011;68:953–955. doi: 10.1001/archneurol.2011.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.38</ArticleId>
            <ArticleId IdType="pubmed">21403004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldassari L.E., Feng J., Clayton B.L., Oh S.-H., Sakaie K., Tesar P.J., Wang Y., Cohen J.A. Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Rev. Neurother. 2019;19:997–1013. doi: 10.1080/14737175.2019.1632192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737175.2019.1632192</ArticleId>
            <ArticleId IdType="pubmed">31215271</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
